Long Build Up Seen In Opko Health Inc (NYSE:OPK)

Posted by Beth Hart October 16, 2013 0 Comment 1269 views

On Tuesday, Opko Health Inc (NYSE:OPK) experienced some unusual options-trading Stock traders bought 24,702 call-options on the company. This is a representation of a 357% rise in comparison to the average daily-volume of 5,400 call-options. In separate company news, Phillip Md Et Al Frost, the company’s Director purchased 7,000 shares of the company’s stock on the open-market in the transaction that was dated 11 October. This stock was bought at an average-price of $10.03/share and the total value of the transaction was $70,210.00.

Analyst rating

Numerous analysts have commented on the Opko Health Inc (NYSE:OPK) stock recently. Barrington Research analysts’ reiterated their “buy” rating on the company shares on 9 September. Separately, Jefferies Group analysts raised their PT on Opko Health Inc (NYSE:OPK) shares from $9.00 to $10.00 on 9 September and have now assigned a “buy” rating on Opko Health Inc (NYSE:OPK)’s stock.

Tuesday’s trading

In Tuesday’s trading, Opko Health Inc (NYSE:OPK) rose by 12.56%. The opening price of the shares was $11.04, which climbed to an intraday high of $12.84 and dipped to a close of $12.28. Approximately 19.14 million shares were traded on Tuesday while an average volume of 4.73 million shares were traded over a 30 day period. The 52-week low of Opko Health Inc (NYSE:OPK) shares is $4.20 and its 52-week high is $12.84. Opko Health Inc (NYSE:OPK) has a market capitalization of $4.96 billion.

About the company

Opko Health Inc (NYSE:OPK) is a multinational pharma & diagnostics company. It is involved in the development of a variety of solutions. These solutions will be used in diagnosing, treating and preventing numerous conditions such as molecular-diagnostics tests, point of care tests, vaccines and pharmaceuticals. Opko Health Inc (NYSE:OPK)’s lead-program is the molecular-diagnostics platform that is used in the development & commercialization of various blood-based tests for different conditions.

About Beth Hart

Beth is from New York. She has two master’s degrees and served as a lecturer in B-School. Her master’s degree is an MBA in Global Management from the University of Phoenix (2010). She has worked for small businesses, public agencies, and large corporations. She does write articles as a freelancer.

View all post by Beth Hart

Write Your Comment